{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:22:16Z","timestamp":1793110936531,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s40265-020-01418-5","type":"journal-article","created":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T07:03:15Z","timestamp":1602745395000},"page":"1859-1864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Imlifidase: First Approval"],"prefix":"10.1007","volume":"80","author":[{"given":"Zaina T.","family":"Al-Salama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"1418_CR1","unstructured":"National Institute for Health Research. Imlifidase for kidney transplantation in highly sensitised patients with chronic kidney disease (NIHR health technology briefing). 2019. http:\/\/www.io.nihr.ac.uk\/wp-content\/uploads\/2019\/07\/11428-Imlifidase-for-Kidney-Transplantation-V1.0-JUL2019-NONCONF.pdf. Accessed 21 Sept 2020."},{"key":"1418_CR2","doi-asserted-by":"publisher","DOI":"10.1097\/tp.0000000000003023","author":"S Ge","year":"2019","unstructured":"Ge S, Chu M, Choi J, et al. Imlifidase inhibits HLA antibody-mediated NK cell activation and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. Transplantation. 2019. https:\/\/doi.org\/10.1097\/tp.0000000000003023.","journal-title":"Transplantation"},{"key":"1418_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6804678","author":"S Sethi","year":"2017","unstructured":"Sethi S, Choi J, Toyoda M, et al. Desensitization: overcoming the immunologic barriers to transplantation. J Immunol Res. 2017. https:\/\/doi.org\/10.1155\/2017\/6804678.","journal-title":"J Immunol Res"},{"key":"1418_CR4","unstructured":"Hansa Biopharma AB. The EU Commission grants conditional approval for Idefirix\u2122 (imlifidase) in highly sensitized kidney transplant patients in the European Union [media release]. 26 Aug 2020. http:\/\/www.hansabiopharma.com."},{"key":"1418_CR5","unstructured":"European Medicines Agency. Idefirix (imlifidase): EU summary of product characteristics. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/idefirix-epar-product-information_en.pdf. Accessed 21 Sept 2020."},{"key":"1418_CR6","unstructured":"Hansa Biopharma AB. Hansa Biopharma announces exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as pre-treatment ahead of gene therapy in select indications. [media release]. 1 Jul 2020. http:\/\/www.hansabiopharma.com."},{"key":"1418_CR7","unstructured":"Hansa Medical AB. Hansa Medical AB announces cooperation with Cedars-Sinai Medical Center\u2019s Comprehensive Transplant Center and US transplantation expert Stanley Jordan [media release]. 5 Feb 2015. http:\/\/www.hansamedical.com."},{"key":"1418_CR8","unstructured":"Hansa Medical AB. Hansa Medical acquires rights to cancer immunotherapy using antibody-modulating enzymes [media release]. 19 Jul 2016. http:\/\/www.hansamedical.com."},{"key":"1418_CR9","unstructured":"Hansa Medical AB. Hansa Medical year-end report 2014 [media release]. 13 Feb 2015. http:\/\/www.hansamedical.com."},{"key":"1418_CR10","unstructured":"Hansa Medical AB. Hansa Medical granted patents in the United States and Europe for the medical use of IdeS [media release]. 14 Mar 2012. http:\/\/www.hansamedical.com."},{"issue":"7","key":"1418_CR11","doi-asserted-by":"publisher","first-page":"e0132011","DOI":"10.1371\/journal.pone.0132011","volume":"10","author":"L Winstedt","year":"2015","unstructured":"Winstedt L, J\u00e4rnum S, Nordahl EA, et al. Complete removal of extracellular IgG antibodies in a randomized dose-escalation phase I study with the bacterial enzyme IdeS\u2014a novel therapeutic opportunity. PLoS ONE. 2015;10(7):e0132011.","journal-title":"PLoS ONE"},{"issue":"9","key":"1418_CR12","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1111\/ajt.15851","volume":"20","author":"J Lin","year":"2020","unstructured":"Lin J, Boon L, Bockermann R, et al. Desensitization using imlifidase and EndoS enables chimerism induction in allosensitized recipient mice. Am J Transplant. 2020;20(9):2356\u201365.","journal-title":"Am J Transplant"},{"issue":"8","key":"1418_CR13","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1093\/ndt\/gfq115","volume":"25","author":"R Yang","year":"2010","unstructured":"Yang R, Otten MA, Hellmark T, et al. Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes. Nephrol Dial Transplant. 2010;25(8):2479\u201386.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"1418_CR14","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","volume":"26","author":"C Leborgne","year":"2020","unstructured":"Leborgne C, Barbon E, Alexander JM, et al. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies. Nat Med. 2020;26(7):1096\u2013101.","journal-title":"Nat Med"},{"issue":"11","key":"1418_CR15","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1111\/ajt.14733","volume":"18","author":"T Lorant","year":"2018","unstructured":"Lorant T, Bengtsson M, Eich T, et al. Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients. Am J Transplant. 2018;18(11):2752\u201362.","journal-title":"Am J Transplant"},{"issue":"5","key":"1418_CR16","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1056\/NEJMoa1612567","volume":"377","author":"SC Jordan","year":"2017","unstructured":"Jordan SC, Lorant T, Choi J, et al. IgG endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med. 2017;377(5):442\u201353.","journal-title":"N Engl J Med"},{"key":"1418_CR17","unstructured":"Hansa Biopharma AB. Hansa Biopharma: investor presentation [presentation]. In: Citi European Healthcare Conference. 2020."},{"issue":"Suppl 3","key":"1418_CR18","first-page":"327","volume":"19","author":"SC Jordan","year":"2019","unstructured":"Jordan SC, Legendre C, Desai N, et al. Safety and efficacy of imlifidase in highly-sensitized kidney transplant patients: results from a phase 2 study. Am J Transplant. 2019;19(Suppl 3):327\u20138.","journal-title":"Am J Transplant"},{"key":"1418_CR19","unstructured":"Hansa Biopharma AB. Hansa Biopharma announces long term follow-up data that demonstrates 2-year graft survival of 89% after imlifidase treatment and transplantation [media release]. 6 Mar 2020. https:\/\/news.cision.com\/hansa-biopharma-ab\/r\/hansa-biopharma-announces-long-term-follow-up-data-that-demonstrates-2-year-graft-survival-of-89\u2013af,c3053754."},{"key":"1418_CR20","unstructured":"European Medicines Agency. Idefirix (imlifidase): EU assessment report. 2020. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/idefirix-epar-public-assessment-report_en.pdf. Accessed 21 Sept 2020."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01418-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-020-01418-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-020-01418-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T20:23:24Z","timestamp":1634243004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-020-01418-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":20,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1418"],"URL":"https:\/\/doi.org\/10.1007\/s40265-020-01418-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,15]]},"assertion":[{"value":"15 October 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Zaina T. Al-Salama is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability"}}]}}